MAPS, MDMA & Beyond Webinar

MDMA-assisted therapy for PTSD remains a primary focus of MAPS and Lychos Therapeutics. The recent FDA advisory committee meeting concerning the drug application for this therapy served as a significant, though non-binding, event in the ongoing medicalization process. While the committee delivered a negative recommendation regarding current safety and efficacy data, the official FDA decision in August will remain the definitive, although also non-binding, outcome. MAPS emphasizes the distinction between its nonprofit organizational work and the pharmaceutical development efforts carried out by Lychos. Future efforts aim to prioritize scientific consensus and patient outcomes through continued research and responsible education. The organization remains committed to advancing evidence-based practices that address the complexities of drug policy reform and therapeutic accessibility.